[1] JICK H, WATKINS RN, HUNTER JR, et al.Replacement estrogens and endometrial cancer[J]. N Engl J Med, 1979, 300(5): 218-222. [2] PLATT R, DAVIS R, FINKELSTEIN J, et al.Multicenter epidemiologic and health services research on therapeutics in the HMO research network center for education and research on therapeutics[J]. Pharmacoepidemiol Drug Saf, 2001, 10(5): 373-377. [3] PLATT R, CARNAHAN RM, BROWN JS, et al.The U.S. Food and Drug Administration's mini-sentinel program: status and direction[J]. Pharmacoepidemiol Drug Saf, 2012, 21(Suppl 1): 1-8. [4] HUANG TY, HOU L, ANDERSEN A, et al.Incidence of severe uterine bleeding outcomes among oral anticoagulant users and nonusers[J]. Am J Obstet Gynecol, 2021, 226(1):140-143. [5] EWORUKE E, HOU L, ZHANG R, et al.Risk of severe abnormal uterine bleeding associated with rivaroxaban compared with apixaban, dabigatran and warfarin[J]. Drug Saf, 2021, 44(7): 753-763. [6] EWORUKE E, HAUG N, BRADLEY M, et al. Risk of nonmelanoma skin cancer in association with use of hydrochlorothiazide-containing products in the United States[J]. JNCI Cancer Spectr, 2021, 5(2): pkab009. [7] PLATT R, BROWN JS, ROBB M, et al.The FDA sentinel initiative - an evolving national resource[J]. N Engl J Med, 2018, 379(22): 2091-2093. [8] EPSTEIN MM, DUTCHER SK, MARO JC, et al.Validation of an electronic algorithm for Hodgkin and non-Hodgkin lymphoma in ICD-10-CM[J]. Pharmacoepidemiol Drug Saf, 2021, 30(7): 910-917. [9] LO RE V, 3rd, CARBONARI DM, JACOB J, et al. Validity of ICD-10-CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies[J]. Pharmacoepidemiol Drug Saf, 2021, 30(7): 899-909. [10] ANDRADE SE, SHINDE M, MOORE SIMAS TA, et al.Validation of an ICD-10-based algorithm to identify stillbirth in the sentinel system[J]. Pharmacoepidemiol Drug Saf, 2021, 30(9): 1175-1183. [11] GIBSON TB, NGUYEN MD, BURRELL T, et al.Electronic phenotyping of health outcomes of interest using a linked claims-electronic health record database: findings from a machine learning pilot project[J]. J Am Med Inform Assoc, 2021, 28(7): 1507-1517. [12] WANG SV, MARO JC, GAGNE JJ, et al.A general propensity score for signal identification using tree-based scan statistics[J]. Am J Epidemiol, 2021, 190(7): 1424-1433. [13] COLOMA PM, SCHUEMIE MJ, TRIFIRO G, et al.Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project[J]. Pharmacoepidemiol Drug Saf, 2011, 20(1): 1-11. [14] YEE A, MAJUMDAR SR, SIMPSON SH, et al.Statin use in type 2 diabetes mellitus is associated with a delay in starting insulin[J]. Diabet Med, 2004, 21(9): 962-967. [15] LEVESQUE LE, HANLEY JA, KEZOUH A, et al.Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes[J]. BMJ (Clinical research ed), 2010, 340: b5087. [16] Observational Health Data Sciences and Informatics. OMOP Common Data Model[EB/OL]. (2020-03-25)[2021-11-08]. https://www.ohdsi.org/data-standardization/the-common-data-model/. [17] LAMER A, DEPAS N, DOUTRELIGNE M, et al.Transforming French electronic health records into the observational medical outcome partnership's common data model: a feasibility study[J]. Appl Clin Inform, 2020, 11(1): E1. [18] HABERSON A, RINNER C, GALL W.Standardizing Austrians claims data using the OMOP common data model: a feasibility study[J]. Stud Health Technol, 2019, 258: 151-152. [19] BELENKAYA R, GURLEY MJ, GOLOZAR A, et al.Extending the OMOP common data model and standardized vocabularies to support observational cancer research[J]. JCO Clin Cancer Inform, 2021, 5: 12-20. [20] FDA. Food and Drug Administration. Sentinel initiative[EB/OL]. (2020-11-08)[2021-11-20]. https://www.sentinelinitiative.org. [21] WYNER Z, DUBLIN S, CHAMBERS C, et al.The FDA MyStudies app: a reusable platform for distributed clinical trials and real-world evidence studies[J]. JAMIA Open, 2020, 3(4): 500-505. [22] SCHNEEWEISS S.Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics[J]. Pharmacoepidemiol Drug Saf, 2006, 15(5): 291-303. [23] VANDERWEELE TJ, DING P.Sensitivity analysis in observational research: introducing the E-value[J]. Ann Intern Med, 2017, 167(4): 268-274. [24] ZHANG X, STAMEY JD, MATHUR MB.Assessing the impact of unmeasured confounders for credible and reliable real-world evidence[J]. Pharmacoepidemiol Drug Saf, 2020, 29(10): 1219-1227. [25] SONG HB,SHEN CY.Thoughts on the application of electronic healthdata in the post-marketing study of drug safety[J]. China Food Drug Administration Magazine(中国食品药品监管), 2020, 11: 36-47. [26] YANG Y, ZHOU X, GAO S, et al.Evaluation of electronic healthcare databases for post-marketing drug safety surveillance and pharmacoepidemiology in China[J]. Drug Saf, 2018, 41(1): 125-137. [27] SHEN ZJ, XU JF, YE XF, et al.Current status of pharmacovigilance research based on administrative claims database[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(3):129-133. |